Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-986506 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part 1A BMS-986506 Monotherapy Escalation | EXPERIMENTAL | - |
| Part 2A BMS-986506 Monotherapy Expansion | EXPERIMENTAL | - |
| Part 2B BMS-986506 Monotherapy Expansion | EXPERIMENTAL | - |
| Part 3A BMS-986506 + Pumitamig Combination Dose Escalation | EXPERIMENTAL | - |
| Part 3B BMS-986506 + Pumitamig + Ipilimumab Combination Dose Escalation | EXPERIMENTAL | - |
| Part 4A BMS-986506 + Pumitamig Combination Dose Expansion | EXPERIMENTAL | - |
| Part 4B BMS-986506 + Pumitamig + Ipilimumab Combination Dose Expansion | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-986506 | DRUG | Specified dose on specified days |
| Pumitamig | DRUG | Specified dose on specified days |
| Ipilimumab | DRUG | Specified dose on specified days |
Inclusion Criteria * Participants must have histologically confirmed diagnosis of locally advanced or metastatic ccRCC. * For part 1: Participants must have already had at least two different treatment plans in the past, including immunotherapy and a targeted therapy. * For part 2: Participants mus...
BMS-986506 is an investigational small molecule being developed for the treatment of advanced clear cell renal cell carcinoma (ccRCC), a type of kidney cancer. It is currently in Phase 1 clinical development and has not been approved by the FDA.
BMS-986506 is being developed by Bristol-Myers Squibb Company, a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol BMY. The company is conducting a first-in-human study of this investigational drug.
BMS-986506 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The ongoing Phase 1 trial is currently recruiting participants with advanced clear cell renal cell carcinoma.
BMS-986506 is being studied in a Phase 1 clinical trial with the identifier NCT07195682. This first-in-human study is recruiting 281 participants with advanced clear cell renal cell carcinoma at sites in the United States, Canada, France, Italy, and Spain.
No alternative names for BMS-986506 have been disclosed. The drug is identified solely by its development code BMS-986506 in the ongoing clinical trial.